Celldex price target raised to $15 from $9 at Jefferies Jefferies increased its price target on Celldex as the firm believes that the company's pipeline outlook was encouraging. The firm views Celldex as a compelling biotech play with multiple shots on goal and it maintains a Buy rating.
News For CLDX From The Last 14 Days
Check below for free stories on CLDX the last two weeks.
Subscribe for More Information